



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-OPGL [18B2] Standard Size Ab04112-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: 18B2

Alternative Name(s) of Target: CD254; Tumor necrosis factor ligand superfamily member 11; TNFSF11; TNF superfamily member 11; Osteoclast differentiation factor; ODF; Osteoprotegerin ligand; OPGL; OPTB2; Receptor activator of nuclear factor kappa-B ligand; RANKL; hRANKL2; TNF-related activation-induced cytokine; TRANCE; sOdf; TNLG6B

UniProt Accession Number of Target Protein: O14788

Published Application(s): in vivo, NTRL, SPR, ELISA

Published Species Reactivity: Human, Cynomolgus Monkey

Immunogen: The original antibody was generated by immunizing transgenic HuMab mice with purified recombinant OPGL derived from *E. coli* or CHO cells. Sera from immunized mice were tested for antibody binding to OPGL.

Specificity: This antibody is specific for human OPGL. *In vivo* experiments have shown cross reactivity with Cynomolgus Monkey OPGL.

Application Notes: The binding affinity of this antibody's original format (human IgG1) to hOPGL was confirmed by ELISA. Its binding kinetics to hOPGL 140 and hOPGL 158 was measured by SPR analysis; a K_D of 0.211 nM was measured for hOPGL 140. This antibody was evaluated for its neutralizing activity against osteoclast formation induced by Osteoprotegerin ligand (OPGL) using RAW 264.7 cells, as measured by tartrate-resistant acid phosphatase (TRAP) activity; it inhibited osteoclast formation in a dose-dependent manner with an IC_{50} of 80 ng/ml. This antibody's pharmacokinetics and *in vivo* activity were assessed in cynomolgus monkeys — three female cynomolgus monkeys (not greater than five years of age, each weighing between 2 to 5 kgs) received a single subcutaneous dose of 1 mg/kg; serum samples were collected over 56 days to determine the levels of the antibody and analyze bone turnover markers such as serum N-telopeptide (serum N-Tx). The antibody's levels in the serum declined slowly over the testing period; the last measurement on day 56 showed a serum concentration of ~100 ng/ml. Serum N-Tx levels were greatly reduced compared to baseline immediately following injection (~minus 60%), further

decreased to a minimum of ~minus 75% over a period of two weeks, after which they began to increase gradually but remained lower in a statistically significant manner than baseline with a final measurement of ~minus 25% on day 56 (US7718776B2).

Antibody First Published in: [PMID:](#)

Note on publication:

Product Form

Size: 100 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.